Alx oncology announces initial data from aspen-02, the ongoing phase 1 / 2 study of evorpacept in combination with azacitidine, demonstrating safety and preliminary activity in patients with myelodysplastic syndrome

-- complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk mds
ALXO Ratings Summary
ALXO Quant Ranking